These mutations in FLT3 are associated with the aggressiveness of AML, reduce overall survival (Kottaridis et al., 2001), and increase the chances of resistance to therapy and relapse (Rombouts et al., 2000). The gene discussed is FLT3; the disease is acute myeloid leukemia.